Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about the delay in the release of GT20029 phase 2 results by Kintor. It also mentions Minoxidil, finasteride, and RU58841 as treatments for hair loss.

Dr. Bloxham's new channel will discuss verteporfin and other future hair loss treatments. Users express interest and hope for the effectiveness of these treatments.

Pyrilutamide is seen as a last hope for those who can't take finasteride, with promising results reported. However, there's uncertainty about the quality and consistency of Pyrilutamide from black market sources.

Verteporfin and FAK inhibitors being looked at as potential treatments for hair regeneration, with updates on the unofficial off-label human trial being discussed.

PP405 might make minoxidil unnecessary, but finasteride or other 5AR inhibitors may still be needed. PP405 is expected to be expensive and not available until at least 2028, with limited information on its effectiveness.

PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.

User experienced hair loss after surgery and was diagnosed with TE. The doctor recommended PRP therapy, Finasteride, Anatrix pro Hair Serum, a multivitamin, and a lotion and shampoo containing Zinc Pyrithione.

The user underwent a second hair transplant for the crown and mid-scalp, achieving good density. They are using minoxidil, finasteride, and biotin, and considering PRP treatments to enhance growth.

CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.

The conversation discusses a user's 7-month progress with hair loss treatment using oral Propecia (finasteride), topical Minoxidil, and a weekly use of a Drama Pen. Some users ask for details about the Drama Pen, while others make jokes or congratulate the user on their progress.

The conversation discusses the effectiveness of official and gray market Pyrilutamide for hair loss. One user experienced chest pain with the gray market version, while another found the official Koshine version mildly effective.

The user experienced severe scalp itching after using RU58841 and ketoconazole shampoo, despite trying moisturizing treatments. They suspect the issue is related to the propylene glycol in the vehicle and are seeking alternatives.

PP405 is considered as a potential hair regrowth treatment, but users are skeptical due to past product failures. They compare it to Minoxidil and Finasteride, questioning its effectiveness and the intentions of pharmaceutical companies.

The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.

The conversation discusses a hair regrowth treatment containing Minoxidil, Procapil, Sandalore, and caffeine. The focus is on evaluating the effectiveness of this product available on eBay.

The conversation is about finding an affordable source for KX 826 powder for hair loss treatment. One user mentions using it alongside dutasteride and minoxidil.

Lab-grown hair using iPSCs is being explored, but practical applications are limited. Finasteride is suggested as the only current effective treatment.

The conversation is about trying Keratin Microsphere products for hair loss, specifically SAF 100 Pro, but no noticeable results were observed. The user also mentioned using a Hairclub wand.

The conversation is about the long-term safety trial results for pyrilutamide, which are expected soon. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

Kevin's YouTube channel was terminated due to a trademark claim, causing frustration among users who found his hair loss content helpful. Many users expressed support for Kevin, mentioning treatments like finasteride and dutasteride, and hoped for his channel's reinstatement.

PP405 cannot restore extracted hair follicles after a transplant as they are removed, not dormant. Combining verteporphin with wounding and PP405 is suggested but not confirmed effective.

Latisse (bimatoprost) is discussed as a potential treatment for hair growth due to difficulty obtaining PGE2. Users also mention concerns about sourcing reliable products from China.

SCUBE3 is a potential hair loss treatment that people are hopeful about. It may provide a solution without the side effects of finasteride.

RU58841 helped regrow hairline without side effects for a bodybuilder using PEDs. The treatment included RU58841, finasteride, minoxidil, GKH-Cu, microneedling, and HGH.

The conversation humorously discusses hair loss treatments like finasteride and minoxidil, noting minoxidil's toxicity to cats. It jokes about a lion needing hair restoration, with references to hair transplants in Turkey.

The conversation discusses the best carrier for RU58841, comparing Ethanol and PEG400. The user seeks advice on which carrier is more effective.

A female user has experienced severe hair shedding since stopping birth control in late 2022, diagnosed as telogen effluvium with no signs of androgenetic alopecia. Despite healthy living and optimal bloodwork, she continues to shed hair daily but also sees significant regrowth.

Nizoral is a suitable replacement for Ketoconazole, but ensure it contains 2% Ketoconazole. The yellow bottle is recommended and should last 3-4 months if used twice a week.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.